Giant pituitary adenomas comprise about 6-10% of all pituitary tumors.

It is estimated that 5% of pituitary adenoma become invasive and may grow to gigantic sizes (>4 cm in diameter).

They are mostly clinically non-functioning adenomas and occur predominantly in males ¹⁾

see also Giant somatotroph adenoma.

The presenting symptoms are usually secondary to compression of neighboring structures, but also due to partial or total hypopituitarism. Functioning pituitary adenomas give rise to specific symptoms of hormonal hypersecretion.

The use of dopamine agonists is considered a first-line treatment in patients with giant macroprolactinomas. Somatostatin analogs can also be used as primary treatment in cases of growth hormone and thyrotropin producing giant adenomas, although remission of the disease is not achieved in the vast majority of these patients.

The intrinsic complexity of these tumors requires the use of different therapies in a combined or sequential way. A multimodal approach and a therapeutic strategy involving a multidisciplinary team of expert professionals form the basis of the therapeutic success in these patients ²⁾.

The main goal of surgical treatment of giant pituitary adenoma is maximum possible tumor extirpation with minimal side effects, which can be achieved by careful preoperative planning of operative approach, based on directions of tumor extensions and invasiveness. Maximal surgical removal of giant adenomas offers best chances to control tumor growth when followed with adjuvant medical and radiation therapies ³⁾.

While the use of endoscopic approaches has become increasingly accepted in the resection of pituitary adenomas, limited evidence exists regarding the success of this technique for patients with large and giant pituitary adenomas.

Major blood supply of giant pituitary adenomas originates from branches of the infraclinoidal portion of the internal carotid artery, different from normal anterior pituitary gland. Surgical route should depend not only on tumor shape and extension but on feeding systems ⁴⁾.

The main goal of surgical treatment of giant pituitary adenoma is maximum possible tumor extirpation with minimal side effects, which can be achieved by careful preoperative planning of operative approach, based on directions of tumor extensions and invasiveness. Maximal surgical removal of giant adenomas offers best chances to control tumor growth when followed with adjuvant medical and radiation therapies ⁵⁾.

In cases of progressive enlargement of residual lesions, a second endoscopic debulking of the tumor may be considered for control of the disease ⁶⁾.

Giant pituitary adenomas carry higher surgical risks despite recent advances in microsurgical and/or endoscopic surgery, and postoperative acute catastrophic changes without major vessel disturbance are still extremely difficult to predict, may manifest as postoperative pituitary apoplexy, and are associated with very poor outcomes.

Resection of both large and giant pituitary adenomas by microscopic transsphenoidal surgery may be safe and effective surgical technique with low morbidity and mortality ⁷⁾.

Giant pituitary adenoma case series.